Evaluation of the efficacy, safety and tolerability of zerlasiran (SLN360) in adults with elevated Lp(a) at high risk of atherosclerotic cardiovascular disease (ASCVD) events
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
